Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Camber Capital Raises Exposure to CONMED Corporation (CNMD)

Stephen DuBois‘ Camber Capital has raised its holding in CONMED Corporation (NASDAQ:CNMD). The fund revealed holding almost 1.4 million shares of the company, up from 1.0 million disclosed in its latest 13F. Currently, Camber’s stake in Conmed amasses 5.02% of the company’s stock. At the current stock price of the company, the value of the activist stake, amounts to nearly $56.6 million.


The stock of Conmed has gained over 45% since the beginning of the year, sporting a P/E of 31.6. For the previous quarter, the company posted sales worth $179.3 million, and diluted EPS of $0.2, down from $0.32 a year ago. At the end of October, the company increased its quarterly dividend by 33% to $0.20 per share. The dividend will be payable January 6.

Among the hedge funds we track, Camber holds the largest position, followed by Cliff Asness‘ Aqr Capital Management, which owned some 301,700 shares at the end of September, down by 30% over the quarter. The value of Aqr’s stake amounts to $10.3 million. Conan Laughlin‘s North Tide Capital, disclosed in its latest 13F, holding around 239,600 shares, with a reported value of $8.1 million.

Camber Capital is a hedge fund with a strong focus on healthcare stocks. In the past couple of months, the fund reported initiating a 5.4% stake in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), which contains 10 million shares. Also, Camber disclosed in October holding a big stake in BIOLASE Inc (NASDAQ:BIOL), which contains 2.7 million shares, and is equal to 7.3% of common stock.

In the latest 13F, Stephen DuBois’ fund revealed the largest position in its equity portfolio involving Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), in which the fund owns 2.0 million shares, worth $75.6 million, the stake surging by almost 170% over the quarter.

Disclosure: none

Recommended Reading:

Citadel Investment Group Increases Holding in Trulia Inc (TRLA) to 6.5%

Corvex Signs Agreement with Soroban Capital Partners Regarding Williams Companies, Inc. (WMB)

David Blood, Al Gore’s Generation Ups Stake in Waters Corporation (WAT)

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!